Evaluation of Low Source of Signal in SCOUT DS (LSS)
This study has been completed.
Sponsor:
VeraLight, Inc.
Information provided by (Responsible Party):
VeraLight, Inc.
ClinicalTrials.gov Identifier:
NCT01339637
First received: April 18, 2011
Last updated: December 3, 2012
Last verified: December 2012
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | April 18, 2011 | ||||
| Last Updated Date | December 3, 2012 | ||||
| Start Date ICMJE | April 2011 | ||||
| Primary Completion Date | September 2011 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals [ Time Frame: 6 months ] [ Designated as safety issue: No ] The primary study endpoint is the relative true positive and relative true negative fractions between the SCOUT DS and FPG test for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL). |
||||
| Original Primary Outcome Measures ICMJE |
Compare SCOUT DS and FPG to Oral Glucose Tolerance Test [ Time Frame: 6 months ] [ Designated as safety issue: No ] The primary study endpoint is the relative true positive and relative true negative fractions between the SCOUT DS and FPG test for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL). |
||||
| Change History | Complete list of historical versions of study NCT01339637 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
Compare SCOUT DS and FPG to HbA1c [ Time Frame: 6 months ] [ Designated as safety issue: No ] Secondary endpoint is to evaluate the receiver operator characteristic area under the curve, sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of SCOUT DS, FPG, and A1C test for detection of abnormal glucose tolerance. |
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Evaluation of Low Source of Signal in SCOUT DS | ||||
| Official Title ICMJE | Evaluation of Low Source of Signal in SCOUT DS | ||||
| Brief Summary | The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score (DRS). |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Cross-Sectional |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Community sample |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Not Provided | ||||
| Study Group/Cohort (s) | Diabetes risk factors
Very dark skin subjects with with diabetes risk factors |
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 196 | ||||
| Completion Date | October 2011 | ||||
| Primary Completion Date | September 2011 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT01339637 | ||||
| Other Study ID Numbers ICMJE | VL-2718 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | VeraLight, Inc. | ||||
| Study Sponsor ICMJE | VeraLight, Inc. | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | VeraLight, Inc. | ||||
| Verification Date | December 2012 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||